Squalene synthase inhibitors

Bibliography

• YALPANI M: Cholesterol-lowering drugs. Chem. Ind. - London (1996):85–89.
   Google Scholar
• ROBERTS WC: Atherosclerotic risk factors - are there ten or is there only one Atherosclerosis (1992) 97:S5–S9.
   Google Scholar
• GRUNDY SM: HMG CoA reductase inhibitors for treatment of hypercholesterolemia. New Engl. J. Med. (1988) 319(1):24–32.
   PubMed Web of Science ®Google Scholar
• POV®, INC.: Worldwide Cardiovascular Rx 2000... the next wave. POV® Reports (1995) 1:407.
   Google Scholar
• SCHECTMAN G, HIATT J: Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann. Intern. Med. (1996) 125(12):990–1000.
   PubMed Web of Science ®Google Scholar
• THE LIPID RESEARCH CLINICS PROGRAM: The Lipid Research Clinics Coronary Primary Prevention Trial Results. J. Am. Med. Assoc. (1984) 251:351–374.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO H, HAAPA K, et al.: Helsinki Heart Study: primary prevention trial with gemlibroAl in middle-aged men with dyslipidemia. New Engl. J. Med. (1987) 317:1237–1245.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RL, et al.: Beneficial effects of colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J. Am. Med. Assoc. (1987) 257:3233–3240.
   PubMed Web of Science ®Google Scholar
• SCANDANAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of choles-terol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. (1995) 333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• BRADFORD RH, SHEAR CL, CHREMOS AN, et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Arch. Intern. Med. (1991) 151:43–49.
   PubMed Web of Science ®Google Scholar
• GARNETT WR: Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. Health-Syst. Pharm. (1995) 52:1639–1645.
   PubMed Web of Science ®Google Scholar
• FOLKERS K, LANGSJOAN P, WILLIS R, et al.: Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA (1990) 87:8931–8934.
   PubMed Web of Science ®Google Scholar
• IMS®: MIDAS Database (1996).
   Google Scholar
• Danielson H, Sjovall J (Eds.), Elsevier, Amsterdam (1985):1–72.
   Google Scholar
• POPJAK G: Inhibition of cholesterol biosynthesis by farnesoic acid and its analogues. Lancet (1960) 1:1270–1273.
   PubMed Web of Science ®Google Scholar
• WALRAVENS PA, GREENE C, FRERMAN FE: Lovastatin, isoprenes and myopathy. Lancet (1989) 2:1097–1098.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN RC, CAREY TF: Cataracts in patients treated with triparanol. J. Am. Med. Assoc. (1962) 181:339–340.
   PubMed Web of Science ®Google Scholar
• FUNG AKL, BAKER WR, FAKHOURY S, et al.: A-87049, a novel potent squalene synthase inhibitor. 211th ACS. New Orleans (24–28 March 1996):MEDI 137.
   Google Scholar
• LEE JY, STEIN HH, WARNER RB, et al.: Oral hypocholesterolemic activity of A-87049, a squalene synthase inhibitor in monkeys and hamsters. FASEB J. (1996) 10(3):A510, Abstract 2942.
   Google Scholar
• IVVASAWA Y, HAYASHI M, NOMOTO T, et al.: Synthesis and biological activity of J-104,118, a novel, potent inhibitor of squalene synthase. Bioorg. Med. Chem Lett. (1995) 5(17):1989–1994.
   Web of Science ®Google Scholar
• IVVASAWA Y, SHIBATA J, MITSUYA M, et al.: J-104,118, a novel and orally-active inhibitor of squalene synthase: Stereoselective synthesis and cholesterol lowering effects in dogs. Bioorg. Med. Chem Lett. (1996) 6(4):463–466.
   Web of Science ®Google Scholar
• DICKSON JK, BILLER SA, MAGNIN DR, et al.: Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the oc-phosphonosulfonic acid moiety. J. Med. Chem. (1996) 39:661–664.
   PubMed Web of Science ®Google Scholar
• HIYOSHI H, YANAGIMACHI M, OTSUKA I, et al.: New lipid-lowering profile of ER-27856, a squalene synthase inhibitor prodrug, in experimental animal models. 66th Congr. Eur. Atheroscler. Soc. Florence (1996):214.
   Google Scholar
• BERGSTROM JD, KURTZ MM, REW DJ, et al.: Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA (1993) 90:80–84.
   PubMed Web of Science ®Google Scholar
• BAXTER A, FITZGERALD BJ, HUTSON JL, et al.: Squalestatin 1, a potent inhibitor of squalene synthase which lowers serum cholesterol in vivo. J Biol. Chem. (1992) 267:11705–11708.
   PubMed Web of Science ®Google Scholar
• NADIN A, NICOLAOU KC: Chemistry and biology of the zaragozic acids (squalestatins). Angew. Chem. InL Ed. Engl. (1996) 35:1622–1656.
   Google Scholar
• A thorough review of the zaragozic acids and the wide variety of semi-synthetic analogues that have been made from them.
   Google Scholar
• HARRIS GH, DUFRESNE C, JOSHUA H, et al.: Isolation, structure determination and squalene synthase activity of L-731120 and L-731128, alkyl citrate analogues of Zaragozic acids A and B. Bioorg. Med. Chem Lett. (1995) 5(20):2403–2408.
   Web of Science ®Google Scholar
• BRINKMAN JA, DAMON RE, FELL JB, et al.: Squalene synthase inhibitors: isoteric replacements of the farnesyl chain of benzyl farnesyl amine. Bioorg. Med. Chem Lett. (1996) 6(21):2491–2494.
   Web of Science ®Google Scholar
• TOZAWA R, TSUBOYA S, SHIROSAKI M, SUNAHARA E: Antihyperlipemics manufactured with Talaromyces. JP-08245691 (1996).
   Google Scholar
• ISAKA M, ISHIHARA T, MATSUDA K, KAKUTA H, MORITANI H: Preparation of quinuclidine derivatives having tricyclic fused hetero rings as squalene synthase inhibitors. WO-9626938 (1996). CA 125:301007.
   Google Scholar
• BROWN GR, CLARKE DS, FOUBISTER At et al.: Synthesis and activity of a novel series of 3-biarylquinudidine squalene synthase inhibitors. J. Med. Chem. (1996) 39:2971–2979.
   PubMed Web of Science ®Google Scholar
• KURTZ MM, BANSAL VS, BOSTEDOR RG, et al.: Mechanism-based toxicity of a squalene synthase inhibitor, Zaragozic acid A, in the rat. FASEB 1 (1995) 9(6):A1 317, Abstract 357.
   Google Scholar
• BOSTEDOR RG, KARKAS JD, GERMERSHAUSEN JI, et al.: Farnesol-derived dicarboxylic acids in the urine of animals treated with a squalene synthase inhibitor or fed farnesol. FASEB 1 (1995) 9(6):A1317, Abstract 358.
   Google Scholar
• BERGSTROM JD, KURTZ MM, BOSTEDOR RG, et al: Mechanism-based toxicity of the zaragozic acids in the dog without cholesterol lowering but efficacious cholesterol lowering without toxicity in the rhesus monkey. FASEB J. (1995) 9(6):A1317, Abstract 359.
   Google Scholar
• BILLER SA, NEUENSCHWANDER K, PONPIPOM M, POULTER CD: Squalene synthase inhibi-tors. Curr. Pharm. Design (1996) 2(1):1–40.
   Web of Science ®Google Scholar
• A thorough review of squalene synthase inhibitors.
   Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• QUESNEY-HUNEENS V, GALICK HA, SIPERSTEIN D, et al.: The dual role of mevalon ate in the cell cyde. 1 Biol. Chem. (1983) 258:378–385.
   Google Scholar
• CORSINI A, MAZZOTTI M, RAITERI M, et al.: Relationship between mevalonate pathway and arterial myocyte proliferation: studies with inhibitors of HMG CoA reductase. Atherosclerosis (1993) 101:117–125.
   PubMed Web of Science ®Google Scholar